Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020

Oct 1, 2020

3 Min Watch

Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020

Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020

Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan

Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses the long-term overall survival analysis of the IMpassion-130 clinical trial investigating the atezolizumab and nab paclitaxel combination in triple negative metastatic breast cancer (TNBC) patients presented at the 2020 ESMO Virtual Congress

© 2025 HealthCentral LLC. All rights reserved.

More Videos

New Phase 3 Data May Shake Up Breast Cancer Care

Stephanie Graff, MD; Erin Frances Cobain, MD; Manali Bhave, MD

Practice Change With Palbociclib in Breast Cancer

Manali Bhave, MD; Stephanie Graff, MD; Erin Frances Cobain, MD

Key Studies in Early Breast Cancer From SABCS 2024

Erin Frances Cobain, MD

Abemaciclib or Ribociclib in Early Breast Cancer?

Erin Frances Cobain, MD; Manali Bhave, MD; Stephanie Graff, MD

More Like This

Oncology Brothers’ Panel on Community Breast Cancer Oncologists

Sarah Premji, MD; Tanmayi Pai, MD

An event hosted by the Oncology Brothers with held meaningful discussions surrounding therapeutic approaches in light of the most recent data.

Oncology Brothers’ Panel on Community Breast Cancer Oncologists

Sarah Premji, MD; Tanmayi Pai, MD

An event hosted by the Oncology Brothers with held meaningful discussions surrounding therapeutic approaches in light of the most recent data.

New Phase 3 Data May Shake Up Breast Cancer Care

Stephanie Graff, MD; Erin Frances Cobain, MD; Manali Bhave, MD

EMBER-3 trial data may lead to a new FDA approval while muddying waters for second-line endocrine therapy in ER-positive, HER2-negative advanced breast cancer.

New Phase 3 Data May Shake Up Breast Cancer Care

Stephanie Graff, MD; Erin Frances Cobain, MD; Manali Bhave, MD

EMBER-3 trial data may lead to a new FDA approval while muddying waters for second-line endocrine therapy in ER-positive, HER2-negative advanced breast cancer.

FDA Actions & News

Cancer Drugs Fast-Tracked by the FDA in December

In December, the U.S. Food and Drug Administration fast-tracked several drugs in oncology. Here are highlights in skin, breast, and prostate cancer, and more.

FDA Actions & News

Cancer Drugs Fast-Tracked by the FDA in December

In December, the U.S. Food and Drug Administration fast-tracked several drugs in oncology. Here are highlights in skin, breast, and prostate cancer, and more.

Practice Change With Palbociclib in Breast Cancer

Manali Bhave, MD; Stephanie Graff, MD; Erin Frances Cobain, MD

New data showing benefit from adding a CDK4/6 inhibitor to endocrine therapy and anti-HER2 therapy in triple-positive advanced breast cancer change practice.

Practice Change With Palbociclib in Breast Cancer

Manali Bhave, MD; Stephanie Graff, MD; Erin Frances Cobain, MD

New data showing benefit from adding a CDK4/6 inhibitor to endocrine therapy and anti-HER2 therapy in triple-positive advanced breast cancer change practice.

From Treating Breast Cancer to Singing About It?

A new song from Moffitt Cancer Center radiologist and musician Dana Ataya, MD, and The ReMissions aims to inspire and empower women about breast cancer.

From Treating Breast Cancer to Singing About It?

A new song from Moffitt Cancer Center radiologist and musician Dana Ataya, MD, and The ReMissions aims to inspire and empower women about breast cancer.

Paclitaxel Data Raise Questions in Early Breast Cancer

Data show two paclitaxel regimens had similar outcomes in high-risk, HR-positive, HER2-negative early breast cancer, raising questions about optimal selection.

Paclitaxel Data Raise Questions in Early Breast Cancer

Data show two paclitaxel regimens had similar outcomes in high-risk, HR-positive, HER2-negative early breast cancer, raising questions about optimal selection.

Phase 3 Data Suggest Potential New Option for TNBC

A phase 3 clinical trial found that neoadjuvant camrelizumab plus chemo improves the rate of pathological complete response in early or locally advanced TNBC.

Phase 3 Data Suggest Potential New Option for TNBC

A phase 3 clinical trial found that neoadjuvant camrelizumab plus chemo improves the rate of pathological complete response in early or locally advanced TNBC.

Key Studies in Early Breast Cancer From SABCS 2024

Erin Frances Cobain, MD

Key studies in HR-positive, HER2-negative early breast cancer at SABCS 2024 inform practice and “springboard to some additional questions,” says Erin Frances Cobain, MD.

Key Studies in Early Breast Cancer From SABCS 2024

Erin Frances Cobain, MD

Key studies in HR-positive, HER2-negative early breast cancer at SABCS 2024 inform practice and “springboard to some additional questions,” says Erin Frances Cobain, MD.

Terminated Breast Cancer Trial Offers ctDNA Insights

The ZEST trial was designed to guide treatment in breast cancer based on MRD, but was ended when it didn’t accrue enough patients. Results may still offer insights.

Terminated Breast Cancer Trial Offers ctDNA Insights

The ZEST trial was designed to guide treatment in breast cancer based on MRD, but was ended when it didn’t accrue enough patients. Results may still offer insights.

Practice Changes for PIK3CA-Mutated Breast Cancer

Azka Ali, MD; Robert A. Figlin, MD, FACP

Azka Ali, MD, and Robert A. Figlin, MD, discuss advances in HR-positive, HER2-negative metastatic breast cancer care for patients with PIK3CA mutations.

Practice Changes for PIK3CA-Mutated Breast Cancer

Azka Ali, MD; Robert A. Figlin, MD, FACP

Azka Ali, MD, and Robert A. Figlin, MD, discuss advances in HR-positive, HER2-negative metastatic breast cancer care for patients with PIK3CA mutations.

Biomarkers Linked to Response in Early TNBC

An exploratory biomarker analysis suggests that tumor mutational burden and T-cell–inflamed gene expression may relate to treatment response in early-stage TNBC.

Biomarkers Linked to Response in Early TNBC

An exploratory biomarker analysis suggests that tumor mutational burden and T-cell–inflamed gene expression may relate to treatment response in early-stage TNBC.

Can Some Patients With DCIS Skip Treatment?

Data from the COMET clinical trial support the safety and efficacy of active monitoring in HR-positive, HER2-negative, low-risk ductal carcinoma in situ.

Can Some Patients With DCIS Skip Treatment?

Data from the COMET clinical trial support the safety and efficacy of active monitoring in HR-positive, HER2-negative, low-risk ductal carcinoma in situ.